EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Effects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial

Hugo E Verdejo, Adolfo Rojas iD, Camila López-Crisosto, Fernando Baraona, Luigi Gabrielli, Vinicius Maracaja-Coutinho iD, Mario Chiong, Sergio Lavandero iD, Pablo F Castro

Journal of Clinical Medicine · 16.02.2023 · 12 (4) · 1571

DOI: 10.3390/jcm12041571 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Journal of Clinical Medicine, online erschienen am 16.02.2023. Verfasst von Hugo E Verdejo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Center for Chronic Diseases (ACCDiS), Division Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Católica de Chile…. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Agencia Nacional de Investigación y Desarrollo, Agencia Nacional de Investigación y Desarrollo (ANID), Chile.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Pulmonary artery hypertension (PAH) is a chronic and progressive disease. Although current therapy has improved the disease prognosis, PAH has a poor survival rate. The key feature leading to disease progression and death is right ventricular (RV) failure. Methods and results: We assessed the role of trimetazidine, a fatty acid beta-oxidation (FAO) inhibitor, in right ventricular function, remodeling, and functional class in PAH patients, with a placebo-controlled double-blind, case-crossover trial. Twenty-seven PAH subjects were enrolled, randomized, and assigned to trimetazidine or placebo for three months and then reallocated to the other study arm. The primary endpoint was RV morphology and function change after three months of treatment. Secondary endpoints were the change in exercise capacity assessed by a 6 min walk test after three months of treatment and the change in pro-BNP and Galectin-3 plasma levels after three months. Trimetazidine use was safe and well-tolerated. After three months of treatment, patients in the trimetazidine group showed a small but significant reduction of RV diastolic area, and a substantial increase in the 6 min walk distance (418 vs. 438 mt, p = 0.023), without significant changes in biomarkers.

Conclusions

A short course of trimetazidine is safe and well-tolerated on PAH patients, and it is associated with significant increases in the 6MWT and minor but significant improvement in RV remodeling. The therapeutic potential of this drug should be evaluated in larger clinical trials.

Schlagwörter

Stichwörter der Autor:innen

6 min walk testfatty acid beta-oxidation inhibitorpro-BNPpulmonary artery hypertensionright ventricular failuretrimetazidine

Autor:innen und Institutionen

  • Advanced Center for Chronic Diseases (ACCDiS), Division Enfermedades Cardiovasculares, Facultad de Medicina, Pontificia Universidad Católica de Chile, Santiago 8330077, Chile.
  • Advanced Center for Chronic Diseases (ACCDiS), Facultad de Ciencias Químicas y Farmacéuticas & Facultad de Medicina, Universidad de Chile, Santiago 8380492, Chile.
  • Department of Internal Medicine, Cardiology Division, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

ORCID-Profile: Adolfo Rojas, Vinicius Maracaja-Coutinho, Sergio Lavandero

Förderung

  • Agencia Nacional de Investigación y Desarrollo
  • Agencia Nacional de Investigación y Desarrollo (ANID), Chile

Zitieren

APA

Verdejo, H. E., Rojas, A., López-Crisosto, C., Baraona, F., Gabrielli, L., Maracaja-Coutinho, V., Chiong, M., Lavandero, S., & Castro, P. F. (2023). Effects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial. Journal of Clinical Medicine, 12(4), 1571. https://doi.org/10.3390/jcm12041571

Vancouver

Verdejo HE, Rojas A, López-Crisosto C, Baraona F, Gabrielli L, Maracaja-Coutinho V, et al. Effects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial. Journal of Clinical Medicine. 2023;12(4):1571. doi:10.3390/jcm12041571

BibTeX
@article{Verdejo2023,
  author = {Verdejo, Hugo E and Rojas, Adolfo and López-Crisosto, Camila and Baraona, Fernando and Gabrielli, Luigi and Maracaja-Coutinho, Vinicius and Chiong, Mario and Lavandero, Sergio and Castro, Pablo F},
  title = {Effects of Trimetazidine on Right Ventricular Function and Ventricular Remodeling in Patients with Pulmonary Artery Hypertension: A Randomised Controlled Trial},
  journal = {Journal of Clinical Medicine},
  year = {2023},
  volume = {12},
  number = {4},
  pages = {1571},
  doi = {10.3390/jcm12041571}
}
Kostenlos starten →